|
1.
|
Oh SC: Update of adjuvant chemotherapy for
resected gastric cancer. J Gastric Cancer. 12:3–6. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Schwarz RE and Smith DD: Clinical impact
of lymphadenectomy extent in resectable gastric cancer of advanced
stage. Ann Surg Oncol. 14:317–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
4.
|
Pyrhonen S, Kuitunen T, Nyandoto P and
Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with non-resectable gastric cancer. Br J Cancer.
71:587–591. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Matsubara J, Shimada Y, Kato K, et al:
Phase II study of bolus 5-fluorouracil and leucovorin combined with
weekly paclitaxel as first-line therapy for advanced gastric
cancer. Oncology. 81:291–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Boku N, Yamamoto S, Fukuda H, et al:
Fluorouracil versus combination of irinotecan plus cisplatin versus
S-1 in metastatic gastric cancer: a randomised phase 3 study.
Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Ohtsu A, Shah MA, Van Cutsem E, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: a randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Okada K, Fujiwara Y, Takahashi T, et al:
Overexpression of forkhead box M1 transcription factor (FOXM1) is a
potential prognostic marker and enhances chemoresistance for
docetaxel in gastric cancer. Ann Surg Oncol. 20:1035–1043. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Elsadek B and Kratz F: Impact of albumin
on drug delivery - new applications on the horizon. J Control
Release. 157:4–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Gradishar WJ, Tjulandin S, Davidson N, et
al: Phase III trial of nanoparticle albumin-bound paclitaxel
compared with polyethylated castor oil-based paclitaxel in women
with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Gradishar WJ: Albumin-bound paclitaxel: a
next-generation taxane. Expert Opin Pharmacother. 7:1041–1053.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Coleman RL, Brady WE, McMeekin DS, et al:
A phase II evaluation of nanoparticle, albumin-bound (nab)
paclitaxel in the treatment of recurrent or persistent
platinum-resistant ovarian, fallopian tube, or primary peritoneal
cancer: a Gynecologic Oncology Group study. Gynecol Oncol.
122:111–115. 2011. View Article : Google Scholar
|
|
13.
|
Kottschade LA, Suman VJ, Amatruda T III,
et al: A phase II trial of nab-paclitaxel (ABI-007) and carboplatin
in patients with unresectable stage IV melanoma: a North Central
Cancer Treatment Group Study, N057E (1). Cancer. 117:1704–1710.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Socinski MA, Bondarenko I, Karaseva NA, et
al: Weekly nabpaclitaxel in combination with carboplatin versus
solvent-based paclitaxel plus carboplatin as first-line therapy in
patients with advanced non-small-cell lung cancer: final results of
a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Volk LD, Flister MJ, Chihade D, Desai N,
Trieu V and Ran S: Synergy of nab-paclitaxel and bevacizumab in
eradicating large orthotopic breast tumors and preexisting
metastases. Neoplasia. 13:327–338. 2011.PubMed/NCBI
|
|
16a.
|
Von Hoff DD, Ramanathan RK, Borad MJ, et
al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: a phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011.PubMed/NCBI
|
|
16b.
|
Zhang C, Awasthi N, Schwarz MA, Hinz S and
Schwarz RE: Superior antitumor activity of nanoparticle
albumin-bound paclitaxel in experimental gastric cancer. PLoS One.
8:e580372013. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Awasthi N, Yen PL, Schwarz MA and Schwarz
RE: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to
enhance chemotherapy and antiangiogenic response in pancreatic
cancer. J Cell Biochem. 113:784–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Byun DS, Cho K, Ryu BK, et al: Frequent
monoallelic deletion of PTEN and its reciprocal associatioin with
PIK3CA amplification in gastric carcinoma. Int J Cancer.
104:318–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Li VS, Wong CW, Chan TL, et al: Mutations
of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Smyth EC and Cunningham D: Targeted
therapy for gastric cancer. Curr Treat Options Oncol. 13:377–389.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Wong H and Yau T: Targeted therapy in the
management of advanced gastric cancer: are we making progress in
the era of personalized medicine? Oncologist. 17:346–358. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Serra V, Markman B, Scaltriti M, et al:
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and
inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Maira SM, Stauffer F, Brueggen J, et al:
Identification and characterization of NVP-BEZ235, a new orally
available dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor with potent in vivo antitumor activity. Mol
Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Jegg AM, Ward TM, Iorns E, et al: PI3K
independent activation of mTORC1 as a target in lapatinib-resistant
ERBB2+ breast cancer cells. Breast Cancer Res Treat.
136:683–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Fuereder T, Wanek T, Pflegerl P, et al:
Gastric cancer growth control by BEZ235 in vivo does not correlate
with PI3K/mTOR target inhibition but with [18F]FLT
uptake. Clin Cancer Res. 17:5322–5332. 2011.PubMed/NCBI
|
|
26.
|
Quintas-Cardama A and Verstovsek S:
Molecular pathways: Jak/STAT pathway: mutations, inhibitors and
resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Van de Bor V, Zimniak G, Cerezo D, Schaub
S and Noselli S: Asymmetric localisation of cytokine mRNA is
essential for JAK/STAT activation during cell invasiveness.
Development. 138:1383–1393. 2011.PubMed/NCBI
|
|
28.
|
Xu R, Nakano K, Iwasaki H, et al: Dual
blockade of phosphatidylinositol 3′-kinase and mitogen-activated
protein kinase pathways overcomes paclitaxel-resistance in
colorectal cancer. Cancer Lett. 306:151–160. 2011.
|
|
29.
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann NY Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Sun H, Yu T and Li J: Co-administration of
perifosine with paclitaxel synergistically induces apoptosis in
ovarian cancer cells: more than just AKT inhibition. Cancer Lett.
310:118–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Hou H, Zhang Y, Huang Y, et al: Inhibitors
of phosphatidylinositol 3′-kinases promote mitotic cell death in
HeLa cells. PLoS One. 7:e356652012.
|
|
32.
|
Awasthi N, Schwarz MA, Verma V, Cappiello
C and Schwarz RE: Endothelial monocyte activating polypeptide II
interferes with VEGF-induced proangiogenic signaling. Lab Invest.
89:38–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Awasthi N, Zhang C, Ruan W, Schwarz MA and
Schwarz RE: BMS-754807, a small-molecule inhibitor of insulin-like
growth factor-1 receptor/insulin receptor, enhances gemcitabine
response in pancreatic cancer. Mol Cancer Ther. 11:2644–2653. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Zhang C, Awasthi N, Schwarz MA and Schwarz
RE: Establishing a peritoneal dissemination xenograft mouse model
for survival outcome assessment of experimental gastric cancer. J
Surg Res. 182:227–234. 2013. View Article : Google Scholar
|
|
36.
|
Zhang CH, Zhan WH, He YL, Chen CQ, Huang
MJ and Cai SR: Spleen preservation in radical surgery for gastric
cardia cancer. Ann Surg Oncol. 14:1312–1319. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Xu J, Zhang C, He Y, et al: Lymphatic
endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and
metastasis of gastric cancer. Int J Cancer. 130:787–797. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Schwarz RE and Zagala-Nevarez K:
Recurrence patterns after radical gastrectomy for gastric cancer:
prognostic factors and implications for postoperative adjuvant
therapy. Ann Surg Oncol. 9:394–400. 2002. View Article : Google Scholar
|
|
39.
|
Hofheinz RD, Wenz F, Lukan N, et al:
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric
cancer - an extended phase I MARGIT and AIO trial. Int J Radiat
Oncol Biol Phys. 73:142–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kobunai T, Watanabe T and Fukusato T:
Antitumour activity of S-1 in combination with cetuximab on human
gastric cancer cell lines in vivo. Anticancer Res. 31:3691–3696.
2011.PubMed/NCBI
|
|
41.
|
Mueller A, Bachmann E, Linnig M, et al:
Selective PI3K inhibition by BKM120 and BEZ235 alone or in
combination with chemotherapy in wild-type and mutated human
gastrointestinal cancer cell lines. Cancer Chemother Pharmacol.
69:1601–1615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Janku F, Tsimberidou AM, Garrido-Laguna I,
et al: PIK3CA mutations in patients with advanced cancers treated
with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10:558–565.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Brito DA and Rieder CL: Mitotic checkpoint
slippage in humans occurs via cyclin B destruction in the presence
of an active checkpoint. Curr Biol. 16:1194–1200. 2006. View Article : Google Scholar : PubMed/NCBI
|
